Kociolek Larry K
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA
J Clin Microbiol. 2017 May;55(5):1244-1248. doi: 10.1128/JCM.00147-17. Epub 2017 Mar 8.
Because nucleic acid amplification tests (NAATs) do not distinguish infection (CDI) and asymptomatic carriage, the diagnostic predictive value of NAATs is limited when used in patients with a low probability of CDI. In this issue of the , Truong et al. (J. Clin. Microbiol., 55:1276-1284, 2017, https://doi.org/10.1128/JCM.02319-16) report significant reductions in hospital-onset CDI and oral vancomycin utilization at their institution following implementation of a novel intervention that leveraged their clinical bioinformatics resources to prevent testing of stools from patients without clinically significant diarrhea and in patients with recent laxative use.
由于核酸扩增检测(NAATs)无法区分感染性艰难梭菌感染(CDI)和无症状携带,因此当用于CDI可能性较低的患者时,NAATs的诊断预测价值有限。在本期的《 》杂志中,Truong等人(《临床微生物学杂志》,55:1276 - 1284,2017,https://doi.org/10.1128/JCM.02319 - 16)报告称,在实施一项新的干预措施后,他们机构中医院获得性CDI和口服万古霉素的使用量显著减少。该干预措施利用其临床生物信息学资源,避免对无临床显著腹泻的患者以及近期使用泻药的患者进行粪便检测。